Antihistamine Tablets Recalled Due to Potential Ulcer Drug Contamination

Unique Pharmaceutical Laboratories has initiated a voluntary recall for certain lots of its Cetirizine Hydrochloride Tablets USP, a common allergy medication. The recall is prompted by a potential cross-contamination with ranitidine, a drug primarily used to treat ulcers and acid reflux.

The U.S. Food and Drug Administration (FDA) alerted the public to the issue, stating that ranitidine can cause severe adverse events, including life-threatening hypersensitivity reactions, in individuals sensitive to its ingredients. These reactions can manifest as hypotension, breathing difficulties, and loss of consciousness.

The recall specifically affects four lots of 5 mg cetirizine hydrochloride tablets, packaged in 100-tablet bottles. The discrepancy was reportedly discovered by a pharmacy technician during dispensing. Unique Pharmaceutical Laboratories, in coordination with its distributor Rising Pharma Holdings Inc., is recalling the affected products nationwide.

As of the recall notice, no adverse events related to the recalled tablets had been reported. Consumers who have purchased the affected product are advised not to use it and to contact their healthcare provider if they have experienced any issues. Questions can be directed to Rising Pharma Holdings Inc.